8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

J Hepatol. 2019 Mar;70(3):554-557. doi: 10.1016/j.jhep.2018.10.032. Epub 2018 Dec 5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / administration & dosage
  • Benzimidazoles / administration & dosage*
  • Drug Monitoring / methods*
  • Duration of Therapy*
  • Female
  • Fluorenes / administration & dosage*
  • Hepacivirus* / genetics
  • Hepacivirus* / isolation & purification
  • Hepatitis C, Chronic* / drug therapy
  • Hepatitis C, Chronic* / epidemiology
  • Hepatitis C, Chronic* / virology
  • Humans
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Outcome Assessment, Health Care
  • RNA, Viral / analysis*
  • Sofosbuvir
  • Sustained Virologic Response
  • Uridine Monophosphate / administration & dosage
  • Uridine Monophosphate / analogs & derivatives*

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Fluorenes
  • RNA, Viral
  • ledipasvir, sofosbuvir drug combination
  • Uridine Monophosphate
  • Sofosbuvir